Genetic risk of Alzheimer's disease

Three wishes now that the genie is out of the bottle

Lori Frank, J. Wesson Ashford, Peter J. Bayley, Soo Borson, Herman Buschke, Donna Cohen, Jeffrey L. Cummings, Peter Davies, Margaret Dean, Sanford I. Finkel, Lee Hyer, George Perry, Richard E. Powers, Frederick Schmitt

Research output: Contribution to journalReview article

Abstract

The availability and increasing popularity of direct-to-consumer genetic testing for the presence of an APOE4 allelle led the Alzheimer's Foundation of America Medical, Scientific and Memory Screening Advisory Board to identify three critical areas for attention: 1) ensure consumer understanding of test results; 2) address and limit potential negative consequences of acquiring this information; and 3) support linking results with positive health behaviors, including potential clinical trial participation. Improving access to appropriate sources of genetic counseling as part of the testing process is critical and requires action from clinicians and the genetic testing industry. Standardizing information and resources across the industry should start now, with the input of consumers and experts in genetic risk and health information disclosure. Direct-to-consumer testing companies and clinicians should assist consumers by facilitating consultation with genetic counselors and facilitating pursuit of accurate information about testing.

Original languageEnglish (US)
Pages (from-to)421-423
Number of pages3
JournalJournal of Alzheimer's Disease
Volume66
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Genetic Testing
Industry
Alzheimer Disease
Health Behavior
Genetic Counseling
Disclosure
Referral and Consultation
Clinical Trials
Health
Genie
Direct-To-Consumer Screening and Testing
Counselors

Keywords

  • APOE
  • genetic risk
  • genetic testing
  • late-onset Alzheimer's disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Frank, L., Wesson Ashford, J., Bayley, P. J., Borson, S., Buschke, H., Cohen, D., ... Schmitt, F. (2018). Genetic risk of Alzheimer's disease: Three wishes now that the genie is out of the bottle. Journal of Alzheimer's Disease, 66(2), 421-423. https://doi.org/10.3233/JAD-180629

Genetic risk of Alzheimer's disease : Three wishes now that the genie is out of the bottle. / Frank, Lori; Wesson Ashford, J.; Bayley, Peter J.; Borson, Soo; Buschke, Herman; Cohen, Donna; Cummings, Jeffrey L.; Davies, Peter; Dean, Margaret; Finkel, Sanford I.; Hyer, Lee; Perry, George; Powers, Richard E.; Schmitt, Frederick.

In: Journal of Alzheimer's Disease, Vol. 66, No. 2, 01.01.2018, p. 421-423.

Research output: Contribution to journalReview article

Frank, L, Wesson Ashford, J, Bayley, PJ, Borson, S, Buschke, H, Cohen, D, Cummings, JL, Davies, P, Dean, M, Finkel, SI, Hyer, L, Perry, G, Powers, RE & Schmitt, F 2018, 'Genetic risk of Alzheimer's disease: Three wishes now that the genie is out of the bottle', Journal of Alzheimer's Disease, vol. 66, no. 2, pp. 421-423. https://doi.org/10.3233/JAD-180629
Frank, Lori ; Wesson Ashford, J. ; Bayley, Peter J. ; Borson, Soo ; Buschke, Herman ; Cohen, Donna ; Cummings, Jeffrey L. ; Davies, Peter ; Dean, Margaret ; Finkel, Sanford I. ; Hyer, Lee ; Perry, George ; Powers, Richard E. ; Schmitt, Frederick. / Genetic risk of Alzheimer's disease : Three wishes now that the genie is out of the bottle. In: Journal of Alzheimer's Disease. 2018 ; Vol. 66, No. 2. pp. 421-423.
@article{e9c14a965f1749049b447899d5b12ba0,
title = "Genetic risk of Alzheimer's disease: Three wishes now that the genie is out of the bottle",
abstract = "The availability and increasing popularity of direct-to-consumer genetic testing for the presence of an APOE4 allelle led the Alzheimer's Foundation of America Medical, Scientific and Memory Screening Advisory Board to identify three critical areas for attention: 1) ensure consumer understanding of test results; 2) address and limit potential negative consequences of acquiring this information; and 3) support linking results with positive health behaviors, including potential clinical trial participation. Improving access to appropriate sources of genetic counseling as part of the testing process is critical and requires action from clinicians and the genetic testing industry. Standardizing information and resources across the industry should start now, with the input of consumers and experts in genetic risk and health information disclosure. Direct-to-consumer testing companies and clinicians should assist consumers by facilitating consultation with genetic counselors and facilitating pursuit of accurate information about testing.",
keywords = "APOE, genetic risk, genetic testing, late-onset Alzheimer's disease",
author = "Lori Frank and {Wesson Ashford}, J. and Bayley, {Peter J.} and Soo Borson and Herman Buschke and Donna Cohen and Cummings, {Jeffrey L.} and Peter Davies and Margaret Dean and Finkel, {Sanford I.} and Lee Hyer and George Perry and Powers, {Richard E.} and Frederick Schmitt",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-180629",
language = "English (US)",
volume = "66",
pages = "421--423",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Genetic risk of Alzheimer's disease

T2 - Three wishes now that the genie is out of the bottle

AU - Frank, Lori

AU - Wesson Ashford, J.

AU - Bayley, Peter J.

AU - Borson, Soo

AU - Buschke, Herman

AU - Cohen, Donna

AU - Cummings, Jeffrey L.

AU - Davies, Peter

AU - Dean, Margaret

AU - Finkel, Sanford I.

AU - Hyer, Lee

AU - Perry, George

AU - Powers, Richard E.

AU - Schmitt, Frederick

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The availability and increasing popularity of direct-to-consumer genetic testing for the presence of an APOE4 allelle led the Alzheimer's Foundation of America Medical, Scientific and Memory Screening Advisory Board to identify three critical areas for attention: 1) ensure consumer understanding of test results; 2) address and limit potential negative consequences of acquiring this information; and 3) support linking results with positive health behaviors, including potential clinical trial participation. Improving access to appropriate sources of genetic counseling as part of the testing process is critical and requires action from clinicians and the genetic testing industry. Standardizing information and resources across the industry should start now, with the input of consumers and experts in genetic risk and health information disclosure. Direct-to-consumer testing companies and clinicians should assist consumers by facilitating consultation with genetic counselors and facilitating pursuit of accurate information about testing.

AB - The availability and increasing popularity of direct-to-consumer genetic testing for the presence of an APOE4 allelle led the Alzheimer's Foundation of America Medical, Scientific and Memory Screening Advisory Board to identify three critical areas for attention: 1) ensure consumer understanding of test results; 2) address and limit potential negative consequences of acquiring this information; and 3) support linking results with positive health behaviors, including potential clinical trial participation. Improving access to appropriate sources of genetic counseling as part of the testing process is critical and requires action from clinicians and the genetic testing industry. Standardizing information and resources across the industry should start now, with the input of consumers and experts in genetic risk and health information disclosure. Direct-to-consumer testing companies and clinicians should assist consumers by facilitating consultation with genetic counselors and facilitating pursuit of accurate information about testing.

KW - APOE

KW - genetic risk

KW - genetic testing

KW - late-onset Alzheimer's disease

UR - http://www.scopus.com/inward/record.url?scp=85055979664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055979664&partnerID=8YFLogxK

U2 - 10.3233/JAD-180629

DO - 10.3233/JAD-180629

M3 - Review article

VL - 66

SP - 421

EP - 423

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -